SYRE - Company ID 0001636282
The table below shows Spyre Therapeutics, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | $0.00 | $0.00 |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | - | - | - | - | - | - |
| SG&A |
Spyre Therapeutics, Inc. reported annual revenue of $0.00 for fiscal year 2025. Over the 10 fiscal years shown, annual revenue declined from $4.63M (FY 2016) to $0.00. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $15.23M |
| $11.64M |
| $11.79M |
| $11.94M |
| $10.65M |
| $11.51M |
| Operating income | -$45.64M | -$56.89M | -$41.94M | -$53.57M | -$55.39M | -$44.15M |
| Income tax | $0.00 | $0.00 | $0.00 | -$15.00K | $18.00K | $0.00 |
| Net income | -$69.00M | -$11.18M | -$36.72M | -$44.77M | -$69.03M | -$38.84M |
| EPS (diluted) | -$0.74 | - | - | - | $1.06 | $0.59 |